SCHEMBL3520079

SCHEMBL3520079

O=S(=O)(O)Oc1cc(O)cc(O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 2/20 0.63
PTGS2 P35354 4/20 0.42
LCK P06239 1/20 0.42
BACE1 P56817 1/20 0.40
TYR P14679 2/20 0.40
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
KDM4E B2RXH2 4/20 0.34
LMNA P02545 4/20 0.34
CA12 O43570 4/20 0.34
CA1 P00915 4/20 0.34
CA2 P00918 4/20 0.34
CA7 P43166 4/20 0.34
CA9 Q16790 4/20 0.34
CA14 Q9ULX7 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
HIF1A Q16665 3/20 0.34
CA3 P07451 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30526137 0.91 CISD1 (0.56) CISD1PTGS2LCKBACE1TYR
SCHEMBL379093 0.85 CISD1 (0.54) CISD1PTGS2TYRGAAGLA
SCHEMBL31578652 0.85 CISD1 (0.54) CISD1PTGS2BACE1GAAKDM4E
SCHEMBL7763063 0.85 CISD1 (0.54) CISD1PTGS2LCKTYRGAA
SCHEMBL9053013 0.84 CISD1 (0.50) CISD1TYRGAAGLACA1
SCHEMBL31467447 0.79 CISD1 (1.00) CISD1PTGS2TYRGAAKDM4E
SCHEMBL18091201 0.79 CISD1 (1.00) CISD1PTGS2TYRGAAKDM4E
SCHEMBL30912677 0.79 CISD1 (0.87) CISD1PTGS2LCKTYRGAA
SCHEMBL21247190 0.79 CISD1 (1.00) CISD1PTGS2TYRGAAKDM4E
SCHEMBL19469516 0.79 CISD1 (1.00) CISD1PTGS2TYRGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250162986-A1 Compounds and compositions for neurodegenerative diseases UNIVERSIDADE NOV A DE LISBOA (PT) 2025-05-22 US claimed
EP-4482483-A1 COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2025-01-01 EP claimed
CN-118742304-A Compounds and compositions for neurodegenerative diseases 里斯本新大学 2024-10-01 CN claimed
WO-2023156983-A1 COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2023-08-24 WO claimed
EP-4230201-A1 COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2023-08-23 EP claimed
WO-2000014603-A1 PROCESS FOR PREPARING A COLOR FILTER OR OVERLAY POLAROID CORPORATION (US) 2000-03-16 WO claimed
WO-2000014602-A1 PROCESS FOR FORMING A COLOR FILTER POLAROID CORPORATION (US) 2000-03-16 WO claimed
US-20250162986-A1 Compounds and compositions for neurodegenerative diseases UNIVERSIDADE NOV A DE LISBOA (PT) 2025-05-22 US disclosed
CN-119325372-A Phloroglucinol formulations and methods of use 辛菲特罗制药有限公司 2025-01-17 CN disclosed
EP-4482483-A1 COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2025-01-01 EP disclosed
CN-118742304-A Compounds and compositions for neurodegenerative diseases 里斯本新大学 2024-10-01 CN disclosed
WO-2023156983-A1 COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2023-08-24 WO disclosed
WO-2023156983-A1 COMPOUNDS AND COMPOSITIONS FOR NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2023-08-24 WO disclosed
EP-4230201-A1 COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES UNIVERSIDADE NOVA DE LISBOA (PT) 2023-08-23 EP disclosed
CN-111675683-A Preparation method of proanthocyanidin polymer and proanthocyanidin polymer 西北农林科技大学 2020-09-18 CN disclosed
US-7737308-B1 Methods for nitrating compounds ALLIANT TECHSYSTEMS INC. (US) 2010-06-15 US disclosed
US-20030027060-A1 Photoresist and process for structuring such a photoresist LEDERER KAY (DE) 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250162986-A1 Compounds and compositions for neurodegenerative diseases CLN6, HTT, SNCA CISD1 2185/4885PTGS2 2256/4885LCK 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.